Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

Alnylam Acquires Rights To VEGF Patents From Hybridon

Aug. 5, 2004

By Aaron Lorenzo

Elusys Raises $10.2M Via Series D Financing Round

Aug. 4, 2004

By Aaron Lorenzo

Elusys Raises $10.2M Via Series D Financing Round

Aug. 4, 2004

By Aaron Lorenzo

Though Not Approved, La Jolla's Riquent Begins Phase IV Study

Aug. 3, 2004

By Aaron Lorenzo

Though Not Approved, La Jolla's Riquent Begins Phase IV Study

Aug. 3, 2004

By Aaron Lorenzo

CV Therapeutics Gets Second Ranexa SPA For Angina, ACS

Aug. 2, 2004

By Aaron Lorenzo

CV Therapeutics Gets Second Ranexa SPA For Angina, ACS

Aug. 2, 2004

By Aaron Lorenzo

SGX Acquires First Clinical Drug: Troxatyl For Cancer

July 30, 2004

By Aaron Lorenzo

SGX Acquires First Clinical Drug: Troxatyl For Cancer

July 30, 2004

By Aaron Lorenzo

MannKind IPO Prices Within Range; Shares Close Higher

July 29, 2004

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...
CROI 2026 highlights depression and cognitive vulnerability in HIV
BioWorld
The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences that persist despite antiretroviral...
News in brief
BioWorld Asia
BioWorld Asia briefs for Feb. 24, 2026
Slate Medicines launches with focus on headache disorders
BioWorld Science
Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache...